CA1221630A - Combination enabling to improve absorption of various cations - Google Patents

Combination enabling to improve absorption of various cations

Info

Publication number
CA1221630A
CA1221630A CA000442260A CA442260A CA1221630A CA 1221630 A CA1221630 A CA 1221630A CA 000442260 A CA000442260 A CA 000442260A CA 442260 A CA442260 A CA 442260A CA 1221630 A CA1221630 A CA 1221630A
Authority
CA
Canada
Prior art keywords
calcium
microorganism
pharmaceutically acceptable
yeast
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
CA000442260A
Other languages
English (en)
French (fr)
Inventor
Georges S. Grimberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of CA1221630A publication Critical patent/CA1221630A/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medical Informatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA000442260A 1982-12-01 1983-11-30 Combination enabling to improve absorption of various cations Expired CA1221630A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR8220124A FR2536996B1 (fr) 1982-12-01 1982-12-01 Association permettant d'ameliorer l'absorption de divers cations par l'organisme
FR8220124 1983-12-01

Publications (1)

Publication Number Publication Date
CA1221630A true CA1221630A (en) 1987-05-12

Family

ID=9279686

Family Applications (1)

Application Number Title Priority Date Filing Date
CA000442260A Expired CA1221630A (en) 1982-12-01 1983-11-30 Combination enabling to improve absorption of various cations

Country Status (8)

Country Link
US (1) US4591503A (en])
EP (1) EP0113608B1 (en])
JP (1) JPS59110624A (en])
AT (1) ATE52696T1 (en])
CA (1) CA1221630A (en])
DE (2) DE3381554D1 (en])
FR (1) FR2536996B1 (en])
NL (1) NL930117I1 (en])

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2536996B1 (fr) * 1982-12-01 1985-09-27 Grimberg Georges Association permettant d'ameliorer l'absorption de divers cations par l'organisme
CH666184A5 (it) * 1985-08-06 1988-07-15 Seuref Ag Composizione farmaceutica orale a base di ubichinoni.
FR2600890B1 (fr) * 1986-07-03 1990-02-23 Moreau Pierre Nouvelles compositions riches en oligoelements et leurs procedes de fabrication.
ES2032844T3 (es) * 1987-07-09 1993-03-01 Pierre Moreau Nuevos composiciones ricas en oligoelementos y sus procedimientos de fabricacion.
FR2679775B1 (fr) * 1991-08-01 1994-11-18 Grimbert Georges Medicament a base de derives soufres neutralises.
FR2702655B1 (fr) * 1993-03-18 1995-06-16 Grimberg Georges Serge Composition therapeutique nouvelle ayant un effet immunostimulant.
NZ501933A (en) * 1997-07-05 2001-08-31 Nestle Sa Use of lactobacilli in enteral nutritional compositions for improved mineral absorption
JP2004292382A (ja) * 2003-03-27 2004-10-21 Kirin Brewery Co Ltd ミネラル吸収促進剤及び骨粗鬆症用予防及び／又は改善剤

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA503705A (en) * 1954-06-15 J. Miller John Dentifrice containing urea and urease
GB1440217A (en) * 1973-09-26 1976-06-23 Ici Ltd Compositions
US3928567A (en) * 1974-08-26 1975-12-23 Ariel A Andersen Dietary supplement
US4035479A (en) * 1975-11-14 1977-07-12 Celanese Corporation Delayed and sustained urea release compositions
JPS5818068B2 (ja) * 1977-08-29 1983-04-11 出光興産株式会社 風味と分散性が改良された酵母菌体の製造方法
FR2536996B1 (fr) * 1982-12-01 1985-09-27 Grimberg Georges Association permettant d'ameliorer l'absorption de divers cations par l'organisme

Also Published As

Publication number Publication date
NL930117I1 (nl) 1993-11-01
JPS59110624A (ja) 1984-06-26
FR2536996A1 (fr) 1984-06-08
FR2536996B1 (fr) 1985-09-27
ATE52696T1 (de) 1990-06-15
EP0113608A1 (fr) 1984-07-18
DE3381554D1 (de) 1990-06-21
EP0113608B1 (fr) 1990-05-16
DE113608T1 (de) 1985-01-17
US4591503A (en) 1986-05-27
JPH0563452B2 (en]) 1993-09-10

Similar Documents

Publication Publication Date Title
EP0154344B1 (en) Antiviral pharmaceutical preparations and their use
Tefferi et al. Anagrelide as a new platelet-lowering agent in essential thrombocythemia: mechanism of action, efficacy, toxicity, current indications
KR960016582B1 (ko) 위장장해의 치료 및 예방용 약제학적 조성물
HUT77920A (hu) Opiát antagonistát és kalciumsókat tartalmazó gyógyászati készítmények és alkalmazásuk
RABINOWITZ et al. Comparative tissue absorption of oral 14C‐aspirin and topical triethanolamine 14C‐salicylate in human and canine knee joints
JPH10500678A (ja) 新生物疾患および自己免疫疾患の治療または予防のためのマグネシウムベースの製品の使用
DE69835668T2 (de) Magenentleerung fördernde Zubereitung
CA1221630A (en) Combination enabling to improve absorption of various cations
DE3402878A1 (de) Arzneimittel und die verwendung schwerloeslicher calcium- und/oder magnesiumverbindungen als arzneimittel
DE3873232T2 (de) Ein dideoxynukleosid enthaltendes arzneimittel.
WO1992003135A1 (en) Pharmaceutical compositions containing 5-difluoromethoxy-2-[(3,4-dimethoxy-2-pyridyl) methylsulfinyl] benzimidazole and an anti-helicobacter agent for the treatment of gastrointestinal disorders
EP0190851A1 (en) Improved antiinflammatory composition
Soumakis et al. Hypothyroidism in a patient receiving treatment for multidrug-resistant tuberculosis
US4122188A (en) Treatment of hyperlipoproteinemia with a dichloroacetate salt
GB2177918A (en) Pharmaceutical compositions containing procaine
EP0372676A1 (en) Therapeutic preparation and method
DE2820900A1 (de) Arzneimittel zur behandlung von gastritiden, gastroduodenitiden und gastroduodenaler ulcera
CA1174169A (en) Orally active tolciclate and tolnaftate
Jenkins et al. A controlled study of slow-release theophylline and aminophylline in patients with chronic bronchitis
AU629520B2 (en) A medicament
DE69221905T2 (de) Wismutsubsalicylat in form einer einheitsdosis
US5681593A (en) Method and composition for treating psoriasis, seborrheic dermatitis and eczema
CA1207238A (en) Use of haloprogin in the treatment of herpes labialis
US3920848A (en) Topical agent for alleviation of full thickness burns in mammals
Curzon et al. Effect of using different strontium salts on dental caries in the rat

Legal Events

Date Code Title Description
MKEX Expiry
MKEX Expiry

Effective date: 20040512